



Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 26 2024, 4:05 PM EDT

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

Mar 20 2024, 8:30 AM EDT

Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow

Mar 19 2024, 4:10 PM EDT

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	21.1m
Last Price	\$0.16
52-Week	\$0.05 - \$0.155

04/09/2024 03:49 PM EDT

Investor Relations

Kane Biotech Inc.
Nicole Sendey
Investor Relations & Public
Relations
T: 204-453-1301
nsendey@kanebiotech.com

Board of Directors

Marc Edwards

President, Chief Executive Officer, Director

Dr. Robert Huizinga

Director

Georges Morin

Director

Philip Renaud

Director

Kane Biotech Inc.

290-100 Innovation Drive
Winnipeg, MB R3T 6G2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.